Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.

[1]  Y. Eshet,et al.  No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique , 2007, American journal of hematology.

[2]  D. Pennell,et al.  Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long‐term blood transfusions , 2007, British journal of haematology.

[3]  P. Armand,et al.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. , 2007, Blood.

[4]  M. Cazzola,et al.  Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. , 2006, Haematologica.

[5]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Dimitrov,et al.  Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. , 2005, Leukemia research.

[7]  M. Cazzola,et al.  Myelodysplastic syndromes--coping with ineffective hematopoiesis. , 2005, The New England journal of medicine.

[8]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[9]  John P Klein,et al.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.

[10]  L. Ferrucci,et al.  Anemia and decline in physical performance among older persons. , 2003, The American journal of medicine.

[11]  G. Mufti,et al.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.

[12]  D. Pennell,et al.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.

[13]  M. Cazzola,et al.  Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. , 2002, Haematologica.

[14]  J. Porter.  Practical management of iron overload , 2001, British journal of haematology.

[15]  H. Krumholz,et al.  Blood transfusion in elderly patients with acute myocardial infarction. , 2001, The New England journal of medicine.

[16]  N. Andrews.  Disorders of iron metabolism. , 1999, The New England journal of medicine.

[17]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[18]  R. Gleason,et al.  Clinical consequences of acquired transfusional iron overload in adults. , 1981, The New England journal of medicine.

[19]  E. Rachmilewitz,et al.  Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity , 1978, British journal of haematology.